Empagliflozin in Heart Failure with a Preserved Ejection Fraction

20214,387 citationsJournal Articlebronze Open Access

Authors

Stefan D. Anker · Inserm

Javed Butler · Inserm

Gerasimos Filippatos · Inserm

João Pedro Ferreira · Inserm

Edimar Alcides Bocchi · Inserm

Michael Böhm · Inserm

Hans‐Peter Brunner‐La Rocca · Inserm

Abstract

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 16, pp. 1451-1461

DOI: 10.1056/nejmoa2107038

Field-Weighted Citation Impact: 470.52